Published in AIDS Weekly, June 9th, 1997
Created to conduct advanced tests of candidate AIDS vaccines, the HIV Vaccine Efficacy Trials Network (HIVNET) has now enrolled 4,892 high-risk, HIV negative subjects at its eight domestic sites.
The study, funded by the National Institutes of Health, has already yielded one major finding: a large-scale trial of an HIV vaccine is possible in the U.S., according to Connie Celum of the University of Washington, Seattle HIVNET site.
Celum and colleague Haynes Sheppard of the California Department of Health Services (DHS),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.